Hundreds of adults in Kenya have been enrolled in a study to evaluate the safety of Covid-19 vaccines in adults living with HIV. The adults, aged 12 to 64 years, will be given different types of vaccines in a mix-and-match style. The study is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) for up to Sh1.4 billion (US$12.5 million). For instance, it is not clear if people living with HIV are a risk population for SARS-CoV-2 infection and if they have reduced immune responses to Covid-19 vaccination. It is also not clear if this population can be offered mix and match vaccine regimens to boost their immune responses.

Source: The Star May 19, 2022 04:25 UTC